Literature DB >> 15374939

Galectin-3, a novel binding partner of beta-catenin.

Tatsuo Shimura1, Yukinori Takenaka, Souichi Tsutsumi, Victor Hogan, Akira Kikuchi, Avraham Raz.   

Abstract

Galectin-3 (gal-3), a pleiotrophic protein, is an important regulator of tumor metastasis, which like beta-catenin shuttles between the nucleus and the cytosol in a phosphorylation-dependent manner. We report herein that beta-catenin stimulation of cyclin D1 and c-myc expression is gal-3 dependent. Gal-3 binds to beta-catenin/Tcf complex, colocalizes with beta-catenin in the nucleus, and induces the transcriptional activity of Tcf-4 as determined by the TOP/FOPFLASH reporter system. We have identified the beta-catenin-gal-3-binding sequences, which are in the NH2 and COOH termini of the proteins encompassing amino acid residues 1 to 131 and 143 to 250, respectively. These data indicate that gal-3 is a novel binding partner for beta-catenin involved in the regulation of Wnt/beta-catenin signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15374939     DOI: 10.1158/0008-5472.CAN-04-1816

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  72 in total

1.  Modified apple polysaccharide prevents against tumorigenesis in a mouse model of colitis-associated colon cancer: role of galectin-3 and apoptosis in cancer prevention.

Authors:  Yuhua Li; Li Liu; Yinbo Niu; Juan Feng; Yang Sun; Xianghe Kong; Yongchun Chen; Xiaoyan Chen; Hongquan Gan; Shousong Cao; Qibing Mei
Journal:  Eur J Nutr       Date:  2011-04-24       Impact factor: 5.614

2.  Burn control, an adipocyte-specific function for galectin-12.

Authors:  Linda G Baum
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-04       Impact factor: 11.205

Review 3.  Galectin-3 and cancer stemness.

Authors:  Pratima Nangia-Makker; Victor Hogan; Avraham Raz
Journal:  Glycobiology       Date:  2018-04-01       Impact factor: 4.313

4.  Galectin-3 germline variant at position 191 enhances nuclear accumulation and activation of β-catenin in gastric cancer.

Authors:  Seok-Jun Kim; Ji-Young Shin; Teak-Chin Cheong; Il-Ju Choi; Yeon Su Lee; Seok Hee Park; Kyung-Hee Chun
Journal:  Clin Exp Metastasis       Date:  2011-07-13       Impact factor: 5.150

5.  Towards functional glycomics by localization of binding sites for tissue lectins: lectin histochemical reactivity for galectins during diethylstilbestrol-induced kidney tumorigenesis in male Syrian hamster.

Authors:  Sven Saussez; Francois Lorfevre; Denis Nonclercq; Guy Laurent; Sabine André; Fabrice Journé; Robert Kiss; Gérard Toubeau; Hans-Joachim Gabius
Journal:  Histochem Cell Biol       Date:  2006-01-25       Impact factor: 4.304

6.  Regulation of galectin-3 function in mucosal fibroblasts: potential role in mucosal inflammation.

Authors:  E Lippert; M Gunckel; J Brenmoehl; F Bataille; W Falk; J Scholmerich; F Obermeier; G Rogler
Journal:  Clin Exp Immunol       Date:  2008-03-10       Impact factor: 4.330

Review 7.  Nuclear transport of galectin-3 and its therapeutic implications.

Authors:  Tatsuyoshi Funasaka; Avraham Raz; Pratima Nangia-Makker
Journal:  Semin Cancer Biol       Date:  2014-03-19       Impact factor: 15.707

8.  Role of MSC-derived galectin 3 in the AML microenvironment.

Authors:  Peter P Ruvolo; Vivian R Ruvolo; Jared K Burks; YiHua Qiu; Rui-Yu Wang; Elizabeth J Shpall; Leonardo Mirandola; Numsen Hail; Zhihong Zeng; Teresa McQueen; Naval Daver; Sean M Post; Maurizio Chiriva-Internati; Steven M Kornblau; Michael Andreeff
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2018-04-12       Impact factor: 4.739

9.  Galectin-3: a potential target for cancer prevention.

Authors:  Hafiz Ahmed; Prasun Guha; Engin Kaptan; Gargi Bandyopadhyaya
Journal:  Trends Carbohydr Res       Date:  2011

10.  Distinct effects on splicing of two monoclonal antibodies directed against the amino-terminal domain of galectin-3.

Authors:  Richard M Gray; Michael J Davis; Katherine M Ruby; Patricia G Voss; Ronald J Patterson; John L Wang
Journal:  Arch Biochem Biophys       Date:  2008-04-18       Impact factor: 4.013

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.